Proteomics Profiling of Pancreatic Cancer and Pancreatitis for Biomarkers Discovery
- PMID: 31032145
- PMCID: PMC6481958
- DOI: 10.4172/2157-7013.1000287
Proteomics Profiling of Pancreatic Cancer and Pancreatitis for Biomarkers Discovery
Abstract
Pancreatic cancer is one of the most aggressive malignancies with an increase in incidence predicted, particularly in African Americans. Pancreatic cancer is considered a silent disease with poor prognosis and a lack of early biomarkers for detection. Proteomics has been applied in many diseases for identifying or discovering biomarkers. It has long been suggested that chronic pancreatitis may be a risk factor for developing pancreatic cancer. This study identified proteins that are altered in expression in pancreatic cancer and pancreatitis compared to normal using proteomic technology. Proteins were extracted from laser captured micro-dissected tissues and separated in 2-DPAGE and imaged. The protein profiles of pancreatic cancer and pancreatitis are similar but differed with the protein profile of normal adjacent tissues. Representative proteins, overexpressed in tumor and pancreatitis but not normal tissues, were excised from gels, subjected to in-gel digestion, and analyzed by MALDI-TOF mass spectrometry. Proteins identified included transferrin, ER-60 protein, proapolipoprotein, tropomyosin 1, alpha 1 actin precursor, ACTB protein, and gamma 2 propeptide, aldehyde dehydrogenase 1A1, pancreatic lipase and annexin A1. Several proteins, which were shown in pancreatic cancer, were also observed in pancreatitis samples. Understanding the role of these specific proteins and their mechanistic action will give insights into their involvement in pancreatic cancers.
Keywords: 2D-gel; Biomarkers; Lipase; Pancreatic cancer; Pancreatitis; Proteomic.
Figures



Similar articles
-
Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry.Cancer Res. 2004 Dec 15;64(24):9018-26. doi: 10.1158/0008-5472.CAN-04-3262. Cancer Res. 2004. PMID: 15604267
-
A comparative proteomic study of plasma in feline pancreatitis and pancreatic carcinoma using 2-dimensional gel electrophoresis to identify diagnostic biomarkers: A pilot study.Can J Vet Res. 2015 Jul;79(3):184-9. Can J Vet Res. 2015. PMID: 26130850 Free PMC article.
-
[Analysis of pancreatic cancer peripheral blood by comparative proteomics].Zhonghua Wai Ke Za Zhi. 2013 Jan 1;51(1):62-5. Zhonghua Wai Ke Za Zhi. 2013. PMID: 23578431 Chinese.
-
Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer.Mol Cell Proteomics. 2007 Aug;6(8):1331-42. doi: 10.1074/mcp.M700072-MCP200. Epub 2007 May 12. Mol Cell Proteomics. 2007. PMID: 17496331
-
Proteomics for the identification of new prostate cancer biomarkers.Urol Oncol. 2006 May-Jun;24(3):231-6. doi: 10.1016/j.urolonc.2005.11.035. Urol Oncol. 2006. PMID: 16678055 Review.
Cited by
-
Identification of Novel Ligands for Targeted Antifibrotic Therapy of Chronic Pancreatitis.Int J Nanomedicine. 2021 Aug 14;16:5495-5512. doi: 10.2147/IJN.S318331. eCollection 2021. Int J Nanomedicine. 2021. PMID: 34429596 Free PMC article.
-
Predictive Design and Analysis of Drug Transport by Multiscale Computational Models Under Uncertainty.Pharm Res. 2023 Feb;40(2):501-523. doi: 10.1007/s11095-022-03298-8. Epub 2022 Jun 1. Pharm Res. 2023. PMID: 35650448 Free PMC article. Review.
-
Diagnostic Differentiation between Pancreatitis and Pancreatic Cancer: A Scoping Review.Diagnostics (Basel). 2024 Jan 29;14(3):290. doi: 10.3390/diagnostics14030290. Diagnostics (Basel). 2024. PMID: 38337806 Free PMC article.
-
Proteomic meta-analysis unveils new frontiers for biomarkers research in pancreatic carcinoma.Oncogenesis. 2025 Feb 16;14(1):3. doi: 10.1038/s41389-025-00547-4. Oncogenesis. 2025. PMID: 39956821 Free PMC article. Review.
-
Engineering of biomaterials for tumor modeling.Mater Today Adv. 2020 Dec;8:100117. doi: 10.1016/j.mtadv.2020.100117. Epub 2020 Nov 12. Mater Today Adv. 2020. PMID: 34541484 Free PMC article.
References
-
- Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, et al. (2008) Serum CA19–9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas 37: 269–274. - PubMed
-
- Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, et al. (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24: 5313–5327. - PubMed
-
- Marrelli D, Caruso S, Pedrazzani C, Neri A, Fernandes E, et al. (2009) CA19–9 serum levels in obstructive jaundice: Clinical value in benign and malignant conditions. Am J Surg 198: 333–339. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous